GENES, LAW, AND HUMAN RIGHTS
ABSTRACT
Isn’t the patent holder of a gene really God or the person the gene belongs to, and not someone who merely identified it? If celestial bodies belong to the public domain under international law and cannot be privately owned, why should DNA sequences, the very building blocks of life be treated differently? The debate over patenting genetic information is not just about science or law; it is about who owns life itself. Gene patents, CRISPR technology, and biotechnology innovations promise breakthroughs in healthcare, but they also raise questions about access, ethics, and human rights. Can a company claim ownership over the BRCA1 and BRCA2 genes linked to breast cancer? Should the product of nature doctrine prevent monopolization of the human genome? The case of Association for Molecular Pathology v. Myriad Genetics shook the foundations of patent law by ruling that naturally occurring DNA cannot be patented. Yet, the TRIPS Agreement and global patent harmonization continue to shape how nations regulate genomic innovation. This blog explores the intersection of patent law and genetics, weaving together molecular science, legal doctrines, and ethical dilemmas in plain language so that even a layperson can grasp why the future of humanity may hinge on how we answer these questions.
INTRODUCTION
Patents are legal rights granted to inventors, giving them exclusive control over their inventions for a limited time. In simple terms, a patent is like a lock on an idea, ensuring that only the inventor can use, sell, or license it. But what happens when the “invention” is not a machine or a drug, but a gene sequence—the very code of life? This is where patent law collides with genetics. The human genome, DNA sequences, and molecular genetics are not just scientific curiosities; they are the blueprint of our existence. Biotechnology and genetic engineering, including revolutionary tools like CRISPR gene editing, have made it possible to manipulate DNA with precision. Yet, the question remains: should these discoveries be treated as inventions eligible for patents, or as natural phenomena that belong to everyone?
WHO OWNS LIFE’S BLUEPRINT?
The debate over gene patents began when companies like Myriad Genetics sought patents on the BRCA1 and BRCA2 genes, which are linked to breast and ovarian cancer. By holding these patents, Myriad controlled who could test for mutations in these genes, effectively monopolizing access to crucial healthcare. Critics argued that this violated the product of nature doctrine, a principle in patent law that says natural phenomena cannot be patented. To put it simply, you cannot patent a tree you find in the forest, but you can patent a new machine that uses wood from that tree. Similarly, you cannot patent a gene as it exists in the human body, but you might patent a synthetic DNA sequence or a novel method of using it.
The U.S. Supreme Court case Association for Molecular Pathology v. Myriad Genetics (2013) was a turning point. The Court ruled that naturally occurring DNA sequences are not patentable because they are products of nature. However, complementary DNA (cDNA), which is artificially created, can be patented. This distinction highlights the tension between innovation and ownership. While companies argue that patents incentivize research and investment, critics warn that monopolizing genetic resources restricts access to healthcare and undermines human rights.
Biotechnology has advanced rapidly, with CRISPR technology allowing scientists to edit genes with unprecedented accuracy. Imagine being able to “cut and paste” DNA like text in a document. This opens doors to curing genetic diseases, but also raises ethical limits of patenting. Should a company own the right to edit the human genome? Isn’t the patent holder of a gene really God or the person whose body carries it? These questions echo broader debates about public interest in patent law. Just as international law prevents private ownership of celestial bodies, many argue that genetic information should remain in the public domain.
Patent eligibility requires novelty and an inventive step. In plain language, this means the invention must be new and not obvious. But when it comes to DNA, novelty is tricky. The human genome has existed for millennia; scientists merely discovered it. Can discovery alone be considered invention? Critics say no, because discovery is about finding what already exists, while invention is about creating something new. Supporters argue that isolating and identifying genes requires skill and effort, deserving protection. This clash reveals the deeper philosophical question: is life itself an invention or a gift?
Globally, the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) sets minimum standards for patent protection, including biotechnology. Patent harmonization across countries ensures consistency, but it also risks imposing rigid rules that may not fit local ethical or healthcare needs. For example, patents on genetic resources could limit access to affordable medicines in developing countries, raising concerns about equity and justice.
Ownership of genetic resources is not just a legal issue; it is a moral one. Indigenous communities often hold traditional knowledge about plants and genetics, yet corporations patent these resources without fair compensation. This practice, sometimes called “biopiracy,” undermines human rights and public trust. Ethical limits of patenting demand that we balance innovation with fairness. As Nelson Mandela once said, “Overcoming poverty is not a gesture of charity, it is an act of justice.” Similarly, ensuring access to genetic healthcare is not charity—it is justice.
The promise of genomic innovation is immense. Molecular genetics and gene editing could revolutionize medicine, agriculture, and even climate resilience. But patents must not become barriers to progress. Public interest in patent law requires that we prioritize human dignity over profit. As Justice Sonia Sotomayor noted in the Myriad case, “We do not own the building blocks of life.” This quote captures the essence of the debate: patents should encourage creativity, not commodify existence.
CONCLUSION
Patenting genetic information sits at the crossroads of science, law, and ethics. While patents drive innovation, they must not undermine access to healthcare or human rights. The case of Myriad Genetics showed that naturally occurring DNA cannot be owned, reaffirming the product of nature doctrine. Yet, biotechnology and CRISPR continue to challenge the boundaries of patent law. Isn’t the real question whether life itself should ever be locked behind a patent? Just as stars cannot be privately owned, perhaps genes too should remain part of humanity’s shared heritage. The future of patent law must balance novelty and inventive step with fairness, ensuring that genomic innovation benefits all. In the end, the ownership of life’s code should belong not to corporations, but to humanity itself.
REFERENCES
Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299.
Nelson Mandela, Speech at the Launch of the Nelson Mandela Foundation (July 2003).
Sonia Sotomayor, Concurring Opinion, Myriad Genetics Case, 569 U.S. 576 (2013).